This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Leadiant loses Dutch excessive-pricing appeal, wins review of collusion complaint

By Andrew Boyce ( February 14, 2025, 16:04 GMT | Insight) -- Drugmaker Leadiant Biosciences has lost its appeal against a 17 million-euro fine that the Dutch competition authority imposed on it for abusing a dominant position in a landmark case on excessive prices. But the same judges at the Rotterdam District Court criticized the regulator for violating its own case prioritization policy by refusing to probe Leadiant's allegations of coordination by health insurers. The ruling means the regulator will have to reassess that decision.Drugmaker Leadiant Biosciences has lost its appeal against a Dutch competition authority fine for charging excessive prices for chenodeoxycholic acid, or CDCA....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections